Grigoris Gerotziafas Shares The APICAT Study Post Hoc Analysis
Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn:
”APICAT study post hoc analysis, Just published: During extended treatment for cancer-associated VTE, four predictors of clinically relevant bleeding were identified in the overall population of patients treated with apixaban, with no evidence of interaction with the dosing regimen.
Anaemia and/or thrombocytopenia, age 75 years or older, pulmonary embolism as the index event, and male sex were significantly associated with an increased risk of clinically relevant bleeding.
Isabelle Mahé 1 , Céline Chapelle 2 , Philippe Girard 3 , Marc Carrier 4 , Luis Jara Palomares 5 , Charles-Marc Samama 6 , Hélène Helfer 7 , Grigoris Gerotziafas 8 , Silvy Laporte 9 , Eric Vicaut 10 , Patrick Mismetti 11 ; API-CAT Study Group; API-CAT Investigators. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.
Lancet Haematol. 2026 Jan;13(1):e41-e48.”
Read the full article here.
Article: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 9, 2026, 13:11Ron DePinho: A Negative Trial Does Not Repudiate Inflammation as a Cardiovascular Target
-
Sep 9, 2026, 13:10Ahmad Gharehbaghian: Visiting the Alborz Provincial Blood Transfusion Center
-
Sep 9, 2026, 13:09Oraianthi Fiste: New Collection on Cancer-Associated Thrombosis From Mechanisms to Precision Medicine
-
Sep 9, 2026, 13:07Can Özlü: Can the HALP Score Help Identify Thrombotic Risk in Myeloproliferative Neoplasms?
-
Sep 9, 2026, 13:06Ohanna Cavalcanti Bezerra: Why Does DVT Lead to PE in Some Patients but Not Others?
-
Sep 9, 2026, 13:04Usman Shehzad: Transforming Patient Lives with INR Self-Testing
-
Sep 9, 2026, 13:02Edward Lee Carter: Provoked VTE May Not Tell the Whole Story About Recurrence Risk
-
Sep 9, 2026, 13:01Danielle Charissa: Functional Genomics Reveals a Causal TWIST1 Variant in Cardiovascular Disease
-
Sep 9, 2026, 12:59Hussnain Javaid: MCQ – Based on the Recent BSH’s Guideline on TTP Diagnosis